PMID- 12010826
OWN - NLM
STAT- MEDLINE
DCOM- 20020701
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 99
IP  - 11
DP  - 2002 Jun 1
TI  - The clinical significance of human leukocyte antigen (HLA) allele compatibility 
      in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and 
      HLA-DR matched unrelated donors.
PG  - 4200-6
AB  - To improve the clinical outcome of allogeneic hematopoietic stem cell 
      transplantation from an unrelated donor, the identification of human leukocyte 
      antigen (HLA) alleles responsible for immunologic events such as 
      graft-versus-host disease (GVHD), engraftment failure, and graft-versus-leukemia 
      effect is essential. Genomic typing of HLA-A, -B, -C, -DRB1, and -DQB1 was 
      retrospectively performed in 1298 donor-patient pairs in cases where marrow was 
      donated from serologically HLA-A, -B, and -DR compatible donors. Single 
      disparities of the HLA-A, -B, -C, or -DRB1 allele were independent risk factors 
      for acute GVHD, and the synergistic effect of the HLA-C allele mismatch with 
      other HLA allele mismatches on acute GVHD was remarkable. HLA-A and/or HLA-B 
      allele mismatch was found to be a significant factor for the occurrence of 
      chronic GVHD. HLA class I (A, B, and/or C) allele mismatch caused a significantly 
      higher incidence of engraftment failure than HLA match. Significant association 
      of HLA-C allele mismatch with leukemia relapse was not observed. As the result of 
      these events, HLA-A and/or HLA-B allele mismatch reduced overall survival 
      remarkably in both standard-risk and high-risk leukemia cases, whereas the HLA-C 
      mismatch or HLA-class II (DRB1 and/or DQB1) mismatch did not. Furthermore, 
      multiple mismatch of the HLA locus was found to reduce survival in leukemia 
      cases. Thus, the role of the HLA class I allele in unrelated bone marrow 
      transplantation was elucidated. Notably, HLA-C alleles had a different mode from 
      HLA-A or -B alleles for acute GVHD and survival.
FAU - Morishima, Yasuo
AU  - Morishima Y
AD  - Department of Hematology and Chemotherapy, the Division of Epidemiology and 
      Prevention, Aichi Cancer Center, Japan. ymorisim@aichi-cc.jp
FAU - Sasazuki, Takehiko
AU  - Sasazuki T
FAU - Inoko, Hidetoshi
AU  - Inoko H
FAU - Juji, Takeo
AU  - Juji T
FAU - Akaza, Tatsuya
AU  - Akaza T
FAU - Yamamoto, Ken
AU  - Yamamoto K
FAU - Ishikawa, Yoshihide
AU  - Ishikawa Y
FAU - Kato, Shunichi
AU  - Kato S
FAU - Sao, Hiroshi
AU  - Sao H
FAU - Sakamaki, Hisashi
AU  - Sakamaki H
FAU - Kawa, Keisei
AU  - Kawa K
FAU - Hamajima, Nobuyuki
AU  - Hamajima N
FAU - Asano, Shigetaka
AU  - Asano S
FAU - Kodera, Yoshihisa
AU  - Kodera Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Anemia, Aplastic/therapy
MH  - Bone Marrow Transplantation/*immunology
MH  - Female
MH  - Genetic Diseases, Inborn/therapy
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - Graft vs Leukemia Effect/immunology
MH  - HLA-A Antigens/*genetics
MH  - HLA-B Antigens/*genetics
MH  - HLA-DR Antigens/*genetics
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Leukemia/immunology/mortality/*therapy
MH  - Lymphoma/therapy
MH  - Male
MH  - Myelodysplastic Syndromes/therapy
MH  - Recurrence
MH  - Retrospective Studies
MH  - *Tissue Donors
MH  - Treatment Outcome
EDAT- 2002/05/16 10:00
MHDA- 2002/07/02 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/07/02 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - S0006-4971(20)60799-6 [pii]
AID - 10.1182/blood.v99.11.4200 [doi]
PST - ppublish
SO  - Blood. 2002 Jun 1;99(11):4200-6. doi: 10.1182/blood.v99.11.4200.